Orgenesis Profile

8.85
USD 0.05  0.56%
31%
29%

Sale by Universite Libre De Bruxelles of 204396 shares of Orgenesis

Orgenesis Inc insider trading alert for sale of common stock by Universite Libre De Bruxelles, the corporate stakeholder, on March 22, 2018. This event was filed by Orgenesis Inc with SEC on 2018-03-22. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Orgenesis Summary

Orgenesis (ORGS) is traded on OTC Market in USA. It is located in MARYLAND, U.S.A and employs 103 people. Orgenesis is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Micro-Cap' category with current market capitalization of 96.44 M. Orgenesis conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 10.9 M outstanding shares of which 23.29 K shares are now shorted by private and institutional investors with about 0.63 trading days to cover. ORGENESIS INC currently holds about 4.22 M in cash with (6.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39.
Check Orgenesis Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 8.85HorizonTargetOdds Above 8.85
63.15%30 days 8.85 36.77%
Based on normal probability distribution, the odds of Orgenesis to move above current price in 30 days from now is about 36.77% (This Orgenesis probability density function shows the probability of Orgenesis Stock to fall within a particular range of prices over 30 days) .

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Morgan StanleyCommon Shares10.1 K104 K
Panagora Asset Management IncCommon Shares4.6 K47 K
View Orgenesis Diagnostics

Selected Orgenesis Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Orgenesis Against Markets

Risk Adjusted
Performance Score (0 to 100)
7 
Chance of
Financial Distress (0 to 100%)
1 
Equity ratings for Orgenesis are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Orgenesis Inc., a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in USA and traded on OTC Market. It employs 103 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameOrgenesis
CEO of Orgenesis Maryland IncScott CarmerView All
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
LocationMARYLAND, U.S.A
Business Address20271 Goldenrod Lane
ExchangeOTC Market
CUSIP68619K105
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.orgenesis.com
Contact Number480 659 6404
Related EntityBOUT
CurrencyUSD - US Dollar

Diversify with Orgenesis

Build Optimal Portfolios
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Orgenesis to your portfolio

Directors

Orgenesis Corporate Directors
David Sidransky Director
Yaron Adler Director
Marie Bouillez Director
Additionally take a look at Your Equity Center. Please also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.